| DESCRIPTION | - BARGOU et al., Science, (20080000), vol. 321, pages 974 - 7 |
| DESCRIPTION | - BARRETT et al., N Engl J Med, (19940000), vol. 331, pages 1253 - 8 |
| DESCRIPTION | - BEHRENS et al., J Clin Invest, (20110000), vol. 121, no. 6, pages 2264 - 77 |
| DESCRIPTION | - BIERER et al., Curr. Opin. Immun., (19930000), vol. 5, pages 763 - 773 |
| DESCRIPTION | - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426 |
| DESCRIPTION | - BOYCE et al., Annals of Oncology, (20030000), vol. 14, pages 520 - 535 |
| DESCRIPTION | - BRENTJENS et al., Blood, (20110000), vol. 118, pages 4817 - 28 |
| DESCRIPTION | - COLLINS et al., Bone Marrow Transplant, (20000000), vol. 26, no. 5, pages 511 - 6 |
| DESCRIPTION | - COLLINS et al., J Clin Oncol, (19970000), vol. 15, pages 433 - 44 |
| DESCRIPTION | - DROBYSKI et al., Biol Blood Marrow Transplant, (20110000), vol. 17, no. 12, pages 1862 - 8 |
| DESCRIPTION | - GARCIA-MANEROTHOMAS, Hematol Oncol Clin North Am, (20010000), vol. 15, no. 1, pages 163 - 205 |
| DESCRIPTION | - GOUJON et al., Nucleic Acids Res, (20100000), vol. 38, pages W695 - 9 |
| DESCRIPTION | - HENDERSON et al., Immun, (19910000), vol. 73, pages 316 - 321 |
| DESCRIPTION | - HOTFILDER et al., Cancer Research, (20050000), vol. 65, pages 1442 - 9 |
| DESCRIPTION | - HOUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883 |
| DESCRIPTION | - HUSE et al., Science, (19890000), vol. 246, pages 1275 - 1281 |
| DESCRIPTION | - JANKA et al., Annu Rev Med, (20120000), vol. 63, pages 233 - 46 |
| DESCRIPTION | - JENSEN et al., Biol Blood Marrow Transplant, (20100000), vol. 16, pages 1245 - 56 |
| DESCRIPTION | - KALOS et al., "3", Science Translational Medicine, (20110000), pages 95 - 73 |
| DESCRIPTION | - KALOS et al., Science Translational Medicine, (20110000), vol. 3, pages 95 - 73 |
| DESCRIPTION | - KOCHENDERFER et al., Blood, (20100000), vol. 116, pages 4099 - 102 |
| DESCRIPTION | - KOCHENDERFER et al., Blood, (20120000), vol. 119, pages 2709 - 20 |
| DESCRIPTION | - KOHLERMILSTEIN, Nature, (19750000), vol. 256, pages 495 - 497 |
| DESCRIPTION | - KOLB et al., Blood, (19950000), vol. 86, pages 2041 - 50 |
| DESCRIPTION | - LARIMORE et al., J Immunol, (20120000), vol. 189, pages 3221 - 30 |
| DESCRIPTION | - LE HUU et al., J Invest Dermatol, (20120000), vol. 132, no. 12, pages 2752 - 61 |
| DESCRIPTION | - LIU et al., Cell, (19910000), vol. 66, pages 807 - 815 |
| DESCRIPTION | - MILONE et al., Mol Ther, vol. 17, pages 1453 - 64 |
| DESCRIPTION | - OLSON et al., J Transl Med, (20110000), vol. 9, page 26 |
| DESCRIPTION | - PORTER et al., N Engl J Med, (20110000), vol. 365, pages 725 - 33 |
| DESCRIPTION | - PULLEN et al., J Clin Oncol, (19930000), vol. 11, no. 5, pages 839 - 49 |
| DESCRIPTION | - QUEEN et al., Proc. NatL. Acad. Sci. USA, (19890000), vol. 86, pages 10029 - 10033 |
| DESCRIPTION | - ROBINS et al., Blood, (20090000), vol. 114, pages 4099 - 107 |
| DESCRIPTION | - ROSENBERG et al., New Eng. J. of Med, (19880000), vol. 319, page 1676 |
| DESCRIPTION | - SIEVERS et al., Mol Syst Biol, (20110000), vol. 7, page 539 |
| DESCRIPTION | - TANG et al., Br J Haematol, (20080000), vol. 143, pages 84 - 91 |
| DESCRIPTION | - TAWARA et al., Clinical Cancer Research, (20110000), vol. 17, pages 77 - 88 |
| DESCRIPTION | - TILL et al., Blood, (20080000), vol. 112, pages 2261 - 71 |
| DESCRIPTION | - VISEUR et al., Cancer Cell, (20080000), vol. 14, pages 47 - 58 |
| DESCRIPTION | - WARD et al., Nature, (19890000), vol. 341, pages 544 - 546 |
| OPPOSITION | - Anonymous, "Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0", Common Terminology Criteria for Adverse Events (CTCAE), U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES; National Institutes of Health; National Cancer Institute, (20090528), pages 1 - 80, Common Terminology Criteria for Adverse Events (CTCAE), URL: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf, (20240404), XP093147902 |
| OPPOSITION | - Anonymous, "EMA Assessment Report for tocilizumab (EMEA/26276/2009)", (20090201), pages 1 - 55, EMEA European Medicines Agency Evaluation of Medicines for Human Use , URL: https://www.ema.europa.eu/en/documents/assessment-report/roactemra-epar-public-assessment-report_en.pdf, (20240226), XP093134679 |
| OPPOSITION | - Anonymous, "Emily Whitehead's Story: CAR T Cell Therapy for Acute Lymphoblastic Leukemia", Children's Hospital of Philadelphia, (20230101), page 1, Children's Hospital of Philadelphia, URL: https://www.chop.edu/video/emily-whiteheads-story-t-cell-therapy-acute-lymphoblastic-leukemia, (20240301), XP093136788 |
| OPPOSITION | - Anonymous, "Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy - History of Changes for Study: NCT01029366", ClinicalTrials.gov; NCT01029366, (20120607), ClinicalTrials.gov; NCT01029366, URL: https://classic.clinicaltrials.gov/ct2/history/NCT01029366?A=5&B=5&C=merged#StudyPageTop, XP093165860 |
| OPPOSITION | - Anonymous, "Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART-19) - History of Changes for Study: NCT01626495", ClinicalTrials.gov; NCT01626495, (20120621), ClinicalTrials.gov; NCT01626495, URL: https://classic.clinicaltrials.gov/ct2/history/NCT01626495?A=1&B=1&C=merged#StudyPageTop, XP093165867 |
| OPPOSITION | - Ca Jr. Janeway, "T cell-mediated cytotoxicity", Immunobiology: The Immune System in Health and Disease (5th Edition), New York, Garland Science, (20010101), XP093165846 |
| OPPOSITION | - CHARLES P , ELLIOTT M J, DAVIS D, ET AL, "Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.", The Journal of Immunology, Williams & Wilkins Co., US, US , (19990801), vol. 163, no. 3, ISSN 0022-1767, pages 1521 - 1528, XP002620410 |
| OPPOSITION | - D103 Second declaration by Prof. Penack |
| OPPOSITION | - Grady Denise, "In Girl's Last Hope, Altered Immune Cells Beat Leukemia", (20121209), pages 1 - 2, The New York Times, URL: https://www.nytimes.com/2012/12/10/health/a-breakthrough-against-leukemia-using-altered-t-cells.html, (20240226), XP093134698 |
| OPPOSITION | - Hottle Heather, "She's a Fighter", Central Daily Times, (20120531), page A1,A7,A9, Central Daily Times, URL: https://www.centredaily.com/news/article42808797.html, (20240404), XP093147888 |
| OPPOSITION | - Kalos Michael, Levine Bruce L, Porter David L, Katz Sharyn, Grupp Han A, Bagg Adam, June Carl H, "Supplementary Materials for T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients ,with Advanced Leukemia", Science translation Medicine, (20110810), pages 1 - 25, XP093134695 |
| OPPOSITION | - Prostate Cancer Foundation, "Carl H. June, MD - Celebration of Science", Youtube, URL: https://www.youtube.com/watch?v=jQ4pFMpAdO0, (20240404), XP093147898 |
| OPPOSITION | - Sha Beverly S., Hernan Valdez, Rebecca S Gelman, Alan L Landay, Jan Agosti, Ronald Mitsuyasu, Richard B Pollard, Donna Mildvan, Ann Namkung, Debra M Ogata-Arakaki, Lawrence Fox, Scharla Estep, Alejo Erice, Patrick Kilgo, Robert E Walker, Lynne Bancroft, Michael M Lederman, "Effect of Etanerceot (Enbrel) on Interleukin 6, Tumor Necrosis Factor a, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2", AIDS Research and Human Retroviruses, (20020101), vol. 18, no. 9, pages 661 - 665, XP093136757 |
| OPPOSITION | - Tom Whitehead, "Against All Odds", ASCO Post, (20180125), ASCO Post, URL: https://ascopost.com/issues/january-25-2018/against-all-odds/, XP093165875 |
| OPPOSITION | - Unknown, "HIGHLIGHTS OF PRESCRIBING INFORMATION - ACTEMRA (tocilizumab)", (20160923), XP093116873 |
| OPPOSITION | - Elias A. Said; Iman Al‐Reesi; Nawal Al‐Shizawi; Sanjay Jaju; Mohammed S. Al‐Balushi; Crystal Y. Koh; Ali A. Al‐Jabri; Lakshmanan Jeyaseelan, "Defining IL‐6 levels in healthy individuals: A meta‐analysis", JOURNAL OF MEDICAL VIROLOGY, John Wiley & Sons, Inc., US, US , (20201122), vol. 93, no. 6, doi:10.1002/jmv.26654, ISSN 0146-6615, pages 3915 - 3924, XP072516355 |
| OPPOSITION | - Cavaillon J.-M., Adib-Conquy M., "The Pro-Inflammatory Cytokine Cascade", Immune Response in the Critically Ill, Berlin, Heidelberg, Springer Berlin Heidelberg, (20020101), pages 37 - 38, doi:10.1007/978-3-642-57210-4_4, ISBN 978-3-642-57210-4, XP093136804 |
| OPPOSITION | - Marco L. Davila, Diana C. G. Bouhassira, Jae H. Park, Kevin J. Curran, Eric L. Smith, Hollie J. Pegram, Renier Brentjens, "Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies", INTERNATIONAL JOURNAL OF HEMATOLOGY., ELSEVIER SCIENCE PUBLISHERS., NL, NL , (20140401), vol. 99, no. 4, doi:10.1007/s12185-013-1479-5, ISSN 0925-5710, pages 361 - 371, XP055533790 |
| OPPOSITION | - Toshio Tanaka; Masashi Narazaki; Tadamitsu Kishimoto, "Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases", FEBS Letters, NL , (20110310), vol. 585, no. 23, doi:10.1016/j.febslet.2011.03.023, ISSN 0014-5793, pages 3699 - 3709, XP028118458 |
| OPPOSITION | - Ito, K. Chung, K.F. Adcock, I.M., "Update on glucocorticoid action and resistance", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20060301), vol. 117, no. 3, doi:10.1016/j.jaci.2006.01.032, ISSN 0091-6749, pages 522 - 543, XP005396899 |
| OPPOSITION | - Usanarat Anurathapan, Ann M. Leen, Malcolm K. Brenner, Juan F. Vera, "Engineered T cells for cancer treatment", Cytotherapy, ISIS MEDICAL MEDIA, OXFORD,, GB, GB , (20140601), vol. 16, no. 6, doi:10.1016/j.jcyt.2013.10.002, ISSN 1465-3249, pages 713 - 733, XP055465916 |
| OPPOSITION | - GOFFE B, CATHER J C, "ETANERCEPT: AN OVERVIEW", Journal of the American Academy of Dermatology, Mosby, Inc, US, US , (20030801), vol. 49, no. 02, SUPPL., doi:10.1016/mjd.2003.554, ISSN 0190-9622, pages S105 - S111, XP009040453 |
| OPPOSITION | - A Ravelli, A A Grom, E M Behrens, R Q Cron, "Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment", Genes and Immunity, GB , (20120315), vol. 13, no. 4, doi:10.1038/gene.2012.3, ISSN 1466-4879, pages 289 - 298, XP055760284 |
| OPPOSITION | - Richard A Morgan et al, "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Molecular Therapy, Elsevier Inc., US, US , (20100401), vol. 18, no. 4, doi:10.1038/mt.2010.24, ISSN 1525-0016, pages 843 - 851, XP055023624 |
| OPPOSITION | - Richard A Morgan et al, "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Molecular Therapy, US , (20100401), vol. 18, no. 4, doi:10.1038/mt.2010.24, ISSN 1525-0016, pages 843 - 851, XP055023624 |
| OPPOSITION | - RESTIFO, N. et al., "Adoptive immunotherapy for cancer: harnessing the T cell response", Nature Reviews Immunology, (20120322), vol. 12, doi:10.1038/nri3191, pages 269 - 281, XP055034896 |
| OPPOSITION | - Jianshu Wei et al, "The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma", Signal Transduction and Targeted Therapy, (20201201), vol. 5, no. 1, doi:10.1038/s41392-020-00256-x, XP055761280 |
| OPPOSITION | - CHOY, E.H. et al., "Translating IL -6 biology", Nature Reviews Rheumatology, (20200423), vol. 16, doi:10.1038/s41584-020-0419-z, pages 335 - 345, XP037147937 |
| OPPOSITION | - David L. Porter, Bruce L. Levine, Michael Kalos, Adam Bagg, Carl H. June, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", The New England journal of medicine, Massachusetts Medical Society, US, US , (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP002732435 |
| OPPOSITION | - David L. Porter, Bruce L. Levine, Michael Kalos, Adam Bagg, Carl H. June, "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", The New England journal of medicine, US , (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP055579937 |
| OPPOSITION | - Grupp Stephan A., Kalos Michael, Barrett David, Aplenc Richard, Porter David L., Rheingold Susan R., Teachey David T., Chew Anne, Hauck Bernd, Wright J. Fraser, Milone Michael C., Levine Bruce L., June Carl H., "Supplementary Appendix. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia", The New England journal of medicine, Massachusetts Medical Society, US, US , (20130418), vol. 368, no. 16, doi:10.1056/NEJMoa1215134, ISSN 0028-4793, pages 1 - 12, XP093136741 |
| OPPOSITION | - Stephan A. Grupp et al, "Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia", The New England journal of medicine, Massachusetts Medical Society, US, US , (20130418), vol. 368, no. 16, doi:10.1056/NEJMoa1215134, ISSN 0028-4793, pages 1509 - 1518, XP055169041 |
| OPPOSITION | - Stephan A Grupp , Michael Kalos , David Barrett , Richard Aplenc , David L Porter , Susan R Rheingold , David T Teachey , Anne Chew , Bernd Hauck , J Fraser Wright , Michael C Milone , Bruce L Levine , Carl H June, "Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia", The New England journal of medicine, US , (20130418), vol. 368, no. 16, doi:10.1056/NEJMoa1215134, ISSN 0028-4793, pages 1509 - 1518, XP055169041 |
| OPPOSITION | - Prieto-Moure Beatriz, Lloris-Carsí José M., Belda-Antolí Mariola, Toledo-Pereyra Luis H., Cejalvo-Lapeña Dolores, "Allopurinol Protective Effect of Renal Ischemia by Downregulating TNF-α, IL-1β, and IL-6 Response", JOURNAL OF INVESTIGATIVE SURGERY., TAYLOR AND FRANCIS., GB, GB , (20170504), vol. 30, no. 3, doi:10.1080/08941939.2016.1230658, ISSN 0894-1939, pages 143 - 151, XP093136779 |
| OPPOSITION | - Rafael Ponce, "Adverse Consequences of Immunostimulation", Journal of Immunotoxicology, Taylor and Francis Group, US, US , (20080101), vol. 5, no. 1, doi:10.1080/15476910801897920, ISSN 1547-691X, pages 33 - 41, XP093165851 |
| OPPOSITION | - Ivan Nestorov; Ralph Zitnik; Todd DeVries; Arline M. Nakanishi; Andrea Wang; Christopher Banfield, "Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis", British journal of clinical pharmacology, BLACKWELL SCIENTIFIC PUBL., GB, GB , (20060214), vol. 62, no. 4, doi:10.1111/j.1365-2125.2006.02581.x, ISSN 0306-5251, pages 435 - 445, XP071599405 |
| OPPOSITION | - Kalos et al., "T Cells with Chimeric Antigen Receptors have potent antitumor effects", Kalos et al, 2011, (20110810), vol. 3, doi:10.1126/scitranslmed.3002842, page 95, XP002667262 |
| OPPOSITION | - KALOS MICHAEL, ET AL, "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", (20110810), vol. 3, no. 95, doi:10.1126/scitranslmed.3002842, pages 95ra73.1 - 95ra73.11, XP002667262 |
| OPPOSITION | - Michael Kalos , Bruce L Levine, David L Porter, Sharyn Katz, Stephan A Grupp, Adam Bagg, Carl H June, "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Science Translation Medicine, (20110810), vol. 3, no. 95, doi:10.1126/scitranslmed.3002842, pages 1 - 11, XP002667262 |
| OPPOSITION | - TISONCIK, J. et al., "Into the Eye of the Cytokine", Microbiology and Molecular Biology Reviews, (20120305), vol. 76, no. 1, doi:10.1128/MMBR.05015-11, pages 16 - 32, XP055183762 |
| OPPOSITION | - Marc Cartellieri, Michael Bachmann, Anja Feldmann, Claudia Bippes, Slava Stamova, Rebekka Wehner, Achim Temme, Marc Schmitz, "Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.", Journal of Biomedicine and Biotechnology, Hindawi Pub. Corp., (20100101), vol. 2010, no. 956304, doi:10.1155/2010/956304, ISSN 1110-7243, pages 1 - 13, XP002673541 |
| OPPOSITION | - Madhusudan Srinivasan, Foster Martin, Muthuramalingam Sethupathi R., Braybrooke Jeremy P., Wilner Susan, Kaur Kulwinder, Han Cheng, Hoare Susan, Balkwill Frances, Talbot Denis C., Ganesan Trivadi S., Harris Adrian L., "A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer", Clinical Cancer Research, Association for Cancer Research, US, US, (20041001), vol. 10, no. 19, doi:10.1158/1078-0432.CCR-04-0730, ISSN 1078-0432, pages 6528 - 6534, XP093136790 |
| OPPOSITION | - Isao Tawara, Motoko Koyama, Chen Liu, Tomomi Toubai, Dafydd Thomas, Rebecca Evers, Peter Chockley, Evelyn Nieves, Yaping Sun, Kathleen P. Lowler, Chelsea Malter, Norihiro Nishimoto, Geoffrey R. Hill, Pavan Reddy, "Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation", Clinical Cancer Research, Association for Cancer Research, US, US, (20110101), vol. 17, no. 1, doi:10.1158/1078-0432.CCR-10-1198, ISSN 1078-0432, pages 77 - 88, XP055763021 |
| OPPOSITION | - Juliane Gust et al, "Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20180326), vol. 7, no. 12, doi:10.1158/2159-8290.CD-17-0698, ISSN 2159-8274, pages 1404 - 1419, XP055462614 |
| OPPOSITION | - Dominguez Helena, Storgaard Heidi, Rask-Madsen Christian, Steffen Hermann Thomas, Ihlemann Nikolaj, Baunbjerg Nielsen Dorthe, Spohr Camilla, Kober Lars, Vaag Allan, Torp-Pedersen Christian, "Metabolic and Vascular Effects of Tumor Necrosis Factor-α Blockade with Etanercept in Obese Patients with Type 2 Diabetes", JOURNAL OF VASCULAR RESEARCH., KARGER, BASEL., CH, CH , (20050101), vol. 42, no. 6, doi:10.1159/000088261, ISSN 1018-1172, pages 517 - 525, XP093136794 |
| OPPOSITION | - Kanellis John, Watanabe Susumu, Li Jin H., Kang Duk Hee, Li Ping, Nakagawa Takahiko, Wamsley Ann, Sheikh-Hamad David, Lan Hui Y., Feng Lili, Johnson Richard J., "Uric Acid Stimulates Monocyte Chemoattractant Protein-1 Production in Vascular Smooth Muscle Cells Via Mitogen-Activated Protein Kinase and Cyclooxygenase-2", Hypertension, Lippincott Williams & Wilkins, US, US , (20030601), vol. 41, no. 6, doi:10.1161/01.HYP.0000072820.07472.3B, ISSN 0194-911X, pages 1287 - 1293, XP093136800 |
| OPPOSITION | - Simon A. Jones, Jürgen Scheller, Stefan Rose-John, "Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling", The Journal of Clinical Investigation, B M J Group, (20110901), vol. 121, no. 9, doi:10.1172/JCI57158, pages 3375 - 3383, XP055265579 |
| OPPOSITION | - Alten Rieke, "Tocilizumab: A Novel Humanized Anti-Interleukin 6 Receptor Antibody for the Treatment of Patients with Rheumatoid Arthritis", Therapeutic Advances in Musculoskeletal Disease, (20110601), vol. 3, no. 3, doi:10.1177/1759720X11407540, ISSN 1759-720X, pages 133 - 149, XP093136750 |
| OPPOSITION | - N. Nishimoto, K. Terao, T. Mima, H. Nakahara, N. Takagi, T. Kakehi, "Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease", Blood, (20081115), vol. 112, no. 10, doi:10.1182/blood-2008-05-155846, ISSN 00064971, pages 3959 - 3964, XP055046024 |
| OPPOSITION | - B. Jena, G. Dotti, L. J. N. Cooper, "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor", Blood, (20100819), vol. 116, no. 7, doi:10.1182/blood-2010-01-043737, ISSN 00064971, pages 1035 - 1044, XP055021403 |
| OPPOSITION | - James N Kochenderfer , Mark E Dudley, Steven A Feldman, Wyndham H Wilson, David E Spaner, Irina Maric, Maryalice Stetler-Stevenson, Giao Q Phan, Marybeth S Hughes, Richard M Sherry, James C Yang, Udai S Kammula, Laura Devillier, Robert Carpenter, Debbie-Ann N Nathan, Richard A Morgan, Carolyn Laurencot, Steven A Rosenberg, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", Blood, American Society of Hematology, US, US , (20120322), vol. 119, no. 12, doi:10.1182/blood-2011-10-384388, ISSN 0006-4971, pages 2709 - 2720, XP055145503 |
| OPPOSITION | - James N Kochenderfer , Mark E Dudley, Steven A Feldman, Wyndham H Wilson, David E Spaner, Irina Maric, Maryalice Stetler-Stevenson, Giao Q Phan, Marybeth S Hughes, Richard M Sherry, James C Yang, Udai S Kammula, Laura Devillier, Robert Carpenter, Debbie-Ann N Nathan, Richard A Morgan, Carolyn Laurencot, Steven A Rosenberg, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", Blood, US , (20120322), vol. 119, no. 12, doi:10.1182/blood-2011-10-384388, ISSN 0006-4971, pages 2709 - 2720, XP055145503 |
| OPPOSITION | - D. W. Lee, R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed, M. Jensen, S. A. Grupp, C. L. Mackall, "Current concepts in the diagnosis and management of cytokine release syndrome", Blood, AMSTERDAM, NL, AMSTERDAM, NL, (20140710), vol. 124, no. 2, doi:10.1182/blood-2014-05-552729, pages 188 - 195, XP055313556 |
| OPPOSITION | - Nellan Anandani, Cynthia M. Lester Mccully Rafael Cruz Garcia, Nalini Jayaprakash, Brigitte C. Widemann, Daniel W. Lee, Katherine E. Warren, "Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques", Blood, American Society of Hematology, US, US , (20180809), vol. 132, no. 6, doi:10.1182/blood-2017-12-824433, ISSN 0006-4971, pages 662 - 666, XP093136784 |
| OPPOSITION | - Vadhan-Raj Saroj; Fayad Luis; Fanale Michelle; Pro Barbara; Rodriguez Alma; Hagemeister Frederick; Ames Kandice; Bueso-Ramos Carlos E.; Zhou Xiao; McLaughlin Peter; Fowler Nathan; Shah Jatin; Samaniego Felipe; Younes Anas; Kwak Larry; Romaguera Jorge, "Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.", Blood, American Society of Hematology, US, US , (20091120), vol. 114, no. 22, doi:10.1182/blood.V114.22.105.105, ISSN 0006-4971, page 105, XP086688969 |
| OPPOSITION | - Grupp SA. Porter DL. Teachey DT, Barrett DM, Chew A. Suppa E. Levine BL Kalos M, June CH, "CD19-Redirected Chimeric Antigen Receptor T(CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab", Blood, American Society of Hematology, US, US , (20120101), vol. 120, no. 21, doi:10.1182/blood.V120.21.2604.2604, ISSN 0006-4971, page 2604, XP009521968 |
| OPPOSITION | - Grupp Stephan A.; Porter David L; Teachey David T; Barrett David M.; Chew Anne; Suppa Erica; Levine Bruce L.; Kalos Michael; June Carl H., "CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).", Blood, American Society of Hematology, US, US , (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.2604.2604, ISSN 0006-4971, page 2604, XP086659979 |
| OPPOSITION | - Grupp Stephan A.; Porter David L; Teachey David T; Barrett David M.; Chew Anne; Suppa Erica; Levine Bruce L.; Kalos Michael; June Carl H., "CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).", Blood, US , (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.2604.2604, ISSN 0006-4971, page 2604, XP086659979 |
| OPPOSITION | - David L Porter , Stephan A. Grupp , Michael Kalos , Alison W. Loren , Lester Lledo CRNP, Joan Gilmore , Michael C Milone , Anne Chew , Bruce L. Levine , Carl H. June , "717: Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, American Society of Hematology, US, US , (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.717.717, ISSN 0006-4971, pages 1 - 3, XP009511066 |
| OPPOSITION | - David L Porter , Stephan A. Grupp , Michael Kalos , Alison W. Loren , Lester Lledo CRNP, Joan Gilmore , Michael C Milone , Anne Chew , Bruce L. Levine , Carl H. June, "Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, American Society of Hematology, US , (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.717.717, ISSN 0006-4971, pages 1 - 3, XP009511066 |
| OPPOSITION | - Porter David L; Grupp Stephan A.; Kalos Michael; Loren Alison W.; Lledo Lester; Gilmore Joan; Milone Michael C; Chew Anne; Levine Bruce L.; June Carl H., "Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", Blood, American Society of Hematology, US, US , (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.717.717, ISSN 0006-4971, page 717, XP086659443 |
| OPPOSITION | - Michael Kalos , Bruce L. Levine , Timothy L Macatee , Irina Kulikovskaya , Erica Suppa , Bipulendu Jena , Saar I. Gill MBBS , Laurence J N Cooper , Stephan A. Grupp , David L Porter , Carl H. June, "Sustained Functional T Cell Persistence and B Cell Aplasia Following CD 19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD 19+ Malignancy", Blood, (20121116), vol. 120, no. 21, doi:10.1182/blood.V120.21.756.756, pages 1 - 3, XP055760298 |
| OPPOSITION | - P. J. Barnes, "Corticosteroid effects on cell signalling", EUROPEAN RESPIRATORY JOURNAL, European Respiratory Society, GB, GB , (20060201), vol. 27, no. 2, doi:10.1183/09031936.06.00125404, ISSN 0903-1936, pages 413 - 426, XP093165856 |
| OPPOSITION | - Michael Kalos, "Biomarkers in T cell therapy clinical trials", Journal of Translational Medicine, BioMed Central, (20110819), vol. 9, no. 1, doi:10.1186/1479-5876-9-138, ISSN 1479-5876, page 138, XP021092216 |
| OPPOSITION | - Tadamitsu Kishimoto, "Interleukin-6: discovery of a pleiotropic cytokine", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, GB , (20060101), vol. 8, no. Suppl 2, doi:10.1186/ar1916, ISSN 1478-6354, page S2, XP093165891 |
| OPPOSITION | - J S Du Bois, Et Al, "Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma", Journal of Clinical Oncology, American Society of Clinical Oncology, United States, United States , doi:10.1200/JCO.1997.15.3.1052, (19970301), pages 1052 - 1062, Journal of Clinical Oncology, URL: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1030.2878&rep=rep1&type=pdf, (20201217), XP055761070 |
| OPPOSITION | - James N. Kochenderfer et al, "Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20150220), vol. 33, no. 6, doi:10.1200/JCO.2014.56.2025, ISSN 0732-183X, pages 540 - 549, XP055552252 |
| OPPOSITION | - Carlos A Ramos, Gianpietro Dotti, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", Expert Opinion on Biological Therapy, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 14712598, pages 855 - 873, XP055122639 |
| OPPOSITION | - OKUDA, Y., "Review of tocilizumab", Biologics: Targets Online ) and Therapy, (20080307), vol. 2, no. 1, doi:10.2147/BTT.S1828, pages 75 - 82, XP055414628 |
| OPPOSITION | - Meier Florian Mp, Frerix Marc, Hermann Walter, Müller-Ladner Ulf, "Current immunotherapy in rheumatoid arthritis", Immunotherapy, Future Medicine Ltd., GB, GB , (20130901), vol. 5, no. 9, doi:10.2217/imt.13.94, ISSN 1750-743X, pages 955 - 974, XP093147894 |
| OPPOSITION | - Frank R. Brennan, Morton Laura Dill, Spindeldreher Sebastian, Kiessling Andrea, Allenspach Roy, Hey Adam, Muller Patrick, Frings Werner, Sims Jennifer, "Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies", mAbs, (20100501), vol. 2, no. 3, doi:10.4161/mabs.2.3.11782, ISSN 1942-0862, pages 233 - 255, XP055072297 |
| SEARCH | - Malemud Charles J, "Open Access Rheumatology: Research and Reviews Recent advances in neutralizing the iL-6 pathway in arthritis", Open Access Rheumatology: Research and Reviews, (20090101), pages 133 - 150, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074717/pdf/oarrr-1-133.pdf, (20220509), XP055919003 [A] 1-11 |
| SEARCH | - TRIKHA MOHIT ET AL, "Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, (20031015), vol. 9, no. 13, ISSN 1078-0432, pages 4653 - 4665, XP002390745 [A] 1-11 |
| SEARCH | - KEVIN J. CURRAN ET AL, "Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions", THE JOURNAL OF GENE MEDICINE, (20120627), vol. 14, no. 6, doi:10.1002/jgm.2604, ISSN 1099-498X, pages 405 - 415, XP055081970 [A] 1-11 |
| SEARCH | - GRAZYNA LIPOWSKA-BHALLA ET AL, "Targeted immunotherapy of cancer with CAR T cells: achievements and challenges", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20120422), vol. 61, no. 7, doi:10.1007/S00262-012-1254-0, ISSN 1432-0851, pages 953 - 962, XP035074376 [A] 1-11 * the whole document * |
| SEARCH | - RENIER BRENTJENS ET AL, "Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial", MOLECULAR THERAPY, (20100401), vol. 18, no. 4, doi:10.1038/mt.2010.31, ISSN 1525-0016, pages 666 - 668, XP055143817 [A] 1-11 * the whole document * |
| SEARCH | - DAVID L. PORTER ET AL, "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia", NEW ENGLAND JOURNAL OF MEDICINE, (20110825), vol. 365, no. 8, doi:10.1056/NEJMoa1103849, ISSN 0028-4793, pages 725 - 733, XP055052475 [A] 1-11 |
| SEARCH | - TOSHIO TANAKA ET AL, "Therapeutic Targeting of the Interleukin-6 Receptor", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY., US, (20120210), vol. 52, no. 1, doi:10.1146/annurev-pharmtox-010611-134715, ISSN 0362-1642, pages 199 - 219, XP055250351 [A] 1-11 |
| SEARCH | - J. N. KOCHENDERFER ET AL, "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells", BLOOD, (20111208), vol. 119, no. 12, doi:10.1182/blood-2011-10-384388, ISSN 0006-4971, pages 2709 - 2720, XP055145503 [A] 1-11 * the whole document * |
| SEARCH | - GRUPP STEPHAN A ET AL, "CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20121116), vol. 120, no. 21, doi:10.1182/BLOOD.V120.21.2604.2604, ISSN 0006-4971, page 2604, XP086659979 [PX] 1-11 * the whole document * |
| SEARCH | - PORTER DAVID L ET AL, "Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20121116), vol. 120, no. 21, doi:10.1182/BLOOD.V120.21.717.717, ISSN 0006-4971, page 717, XP086659443 [PX] 1-11 * the whole document * |
| SEARCH | - CARLOS A RAMOS ET AL, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", EXPERT OPINION ON BIOLOGICAL THERAPY, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 1471-2598, pages 855 - 873, XP055122639 [A] 1-11 |
